Persistent Drug Shortages in the United States: Analyses and Strategies

Hillary E. Robinson (Editor)

Series: Public Health in the 21st Century, America in the 21st Century: Political, Economic and Social Issues
BISAC: BUS070130



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



From prolonged duration of a disease, to permanent injury, to death, drug shortages have led to harmful outcomes for patients of all ages. Over the last decade, an increasing number of prescription drugs—including life-saving and life-sustaining drugs—have been in short supply, preventing health care providers and patients from accessing medications that are essential for treatment. During shortages, providers—including hospitals, physicians, and pharmacists—may have to use medications that could be less effective for treating conditions or carry unwanted side-effects, if alternatives are available at all.

The immediate cause of drug shortages can generally be traced to a manufacturer halting or slowing production to address quality problems, triggering a supply disruption. Other manufacturers have a limited ability to respond to supply disruptions due to constrained manufacturing capacity. This book reviews the trends in recent drug shortages and describes what is known about their effect on patients and providers; examines the causes of drug shortages; and evaluates the progress FDA has made in addressing drug shortages. (Imprint: Nova)


Chapter 1 - Drug Shortages: Public Health Threat Continues, Despite Efforts to Help Ensure Product Availability (pp. 1-78)
United States Government Accountability Office

Chapter 2 - Statement of Douglas C. Throckmorton, Deputy Director of Regulatory Programs, U.S. Food and Drug Administration. Hearing on ''Examining Drug Shortages and Recent Efforts to Address Them'' (pp. 79-88)

Chapter 3 - Strategic Plan for Preventing and Mitigating Drug Shortages (pp. 89-130)
Food and Drug Administration

Chapter 4 - FDA’s Contribution to the Drug Shortage Crisis (pp. 131-154)
House Committee on Oversight and Government Reform Staff


You have not viewed any product yet.